Immunological effects of interferon-alpha on chronic myelogenous leukemia.
D000328:Adult; D018952:Antigens, CD34 / Q000096:biosynthesis; D017209:Apoptosis; D016207:Cytokines / Q000096:biosynthesis / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013234:Stem Cells / Q000276:immunology; D013997:Time Factors
D018952:Antigens, CD34; D016207:Cytokines; D016898:Interferon-alpha; D007376:Interleukin-2; D015847:Interleukin-4; D007371:Interferon-gamma